Phivida [“fiii-vee-daa”] Holdings Inc (CSE:VIDA) is pleased to provide a corporate update for the second quarter of fiscal 2018. Updates include; new product inventory, brand stewardship, executive appointments, the Canbev project and successful financings.

Key Highlights

  • Production Run Complete: 15,000 units of Vida+ tinctures, 3,000 Units of Vida+ capsules
  • CBD Beverages: CBD-Iced Teas and CBD-Infused Water formulas for mainstream distribution
  • Award Winning Design Agency: Sid Lee and Brian Schmitt now engaged for brand development
  • CanBev Project: WeedMD site assessment, management meetings, operations and strategic planning
  • C-Suite (CEO, CMO and CCO): dedicated to long term value, scalable growth and global expansion

New Inventory

Phivida has completed a manufacturing run of 15,000 units of Vida+ CBD tinctures and 3,000 units of Vida+ CBD capsules (formulated for muscle, bone and joints). This run replenished inventory in preparation of a rollout of the Phivida Enhanced clinical education marketing program in the third quarter of fiscal 2018. Events will host health care practitioners and patients for workshops, and town halls, across the pacific USA. Phivida CBD infused beverages are now undergoing consumer focus groups for full commercialization. The initial focus will be on CBD-Hemp Oil infused Enhanced Waters and Ice Teas – robust growth categories in the US beverage market.

Sid Lee and Brian Schmitt

Phivida has formally retained award-winning global creative agency; Sid Lee, to oversee the evolution of the Phivida brand platform ( Phivida has also engaged the services of Brian Schmitt who will act as a creative director. Mr. Schmitt’s portfolio includes iconic brands like Nike and Apple. The evolution of the Phivida brand and product packaging will begin with in-depth consumer insight research (segmentation, sentiment polls and focus groups) for overarching brand marketing strategy, consistent with Fortune 500 calibre packaged goods companies. With a world-class design agency and creative director in place, Phivida anticipates a best-in-class platform to position the brand as a global leader in the CBD beverage category.

Cannabis Beverages Inc.

On March 8, 2018, the Company and WeedMD Inc. (TSXV: WMD) annouced plans to enter into a joint venture focused on cannabis-infused beverages, called Cannabis Beverages Inc. (“CanBev”). CanBev has plans to develop a production facility at WeedMD’s state-of-the-art greenhouse in Strathroy, Ontario, and will operate one of the first cannabis-infused beverage production facilities in Canada.

On April 26th, Phivida management completed a site assessment of the proposed site for the CanBev Inc. project at the WeedMD facilities in Strathroy, Ontario. Post the tour, WeedMD and Phivida management teams conducted two days of CanBev strategy meetings as well as a formal presentation at the Canaccord corporate head offices in Toronto. Meetings reinforced the collaborative vision for the project, including; organizational, operational, product innovation and distribution strategies for the advancement of the CanBev project, aimed at bringing cannabinoid-infused beverages for the medical and future adult-use cannabis markets.

As a collaborative project, within a house of brands model, the CanBev team will continue to optimize strategies on operations and the distribution of high quality lifestyle-based products for both medicinal and recreational consumer segments. As a CBD-centric brand, Phivida will continue to focus on THC-free medicinal products in Canada while supporting; product innovation, marketing and distribution of all products made at CanBev Inc.

Senior Leadership

Mr. James Bailey was appointed as Chief Executive Officer on March 19th and now oversees all operational departments. Direct reports include Chief Marketing Officer; Mr. Michael Cornwell, and Chief Commercial Officer; Mr. Douglas Campbell. This C-Suite represents the former senior executive of Red Bull Canada and depth of experience, distribution networks, as well as a proven track record of commercializing innovative functional food and beverage categories. The Company now seeks a; Director of E-Commerce, Marketing Communications Manager, Sales & Marketing Coordinator and Field/Inside Sales Managers in key markets across the pacific USA.

Phivida Chief Financial Officer; Mr. Carmelo Marrelli, and President and Chairman; Mr. John Belfontaine are focused on public company operations and administration. The board and advisory maintain corporate governance. Key advisors Hillcrest Merchant Partners and Liberty North Capital steward Phivida within the global capital markets. Phivida recently completed a six-week international roadshow, in ten cities, and three countries, including; institutional accounts in; Montreal, Toronto and Vancouver, accredited investors in the Palm Desert, and hedge fund portfolio managers in the financial districts of New York and London, UK.

Phivida is now fully capitalized to execute its strategic business plan, led by an experienced senior leadership team with proven success in navigating rapid expansion within innovative CBD infused functional food and natural health categories. Management is focused on long term shareholder value through scalable growth.

Equity Financing

Phivida closed a bought-deal short form prospectus financing on April 19th, 2018 with the total issuance of 6,960,000 units at a price of $1.15 per Unit for aggregate gross proceeds of approximately $8.0 million. Each unit consists of one common share and one-half of one common share purchase warrant. Management deemed this equity financing prudent due to volatility in major equity markets during the second quarter of fiscal 2018.

Each whole warrant entitles the holder thereof to purchase one common share for $1.60 for 24 months from the date of issuance. Warrants issued under the financing do not have an acceleration clause and were listed for trading under the symbol VIDA.WT. The capital structure post-closing is now 60,390,889 common shares issued and outstanding with approximately $16.3 million in cash, with no loans, liens, or encumbrances.

Phivida Holdings Inc.

Phivida (pronounced “fi-VEE-da”) is a premier brand of Cannabidiol (“CBD”) infused functional foods, beverages and clinical products poised for global distribution. Using encapsulation technology, Phivida converts phytocannabinoids into water soluble delivery format, enhancing bioavailability, and timed released within the body. Phivida infuses CBD into functional beverages, foods and supplements with a proprietary blend of phytonutraceuticals studied to target a range of conditions, from chronic pain to terminal diseases. The World Anti-Doping Association’s recent decision to lift its ban of CBD from hemp oil and the World Health Organization’s recent report supports the potential benefits of CBD worldwide. Celebrating; Health and Wellness, In Harmony™, Phivida’s mission is to lead the alternative health care sector as the benchmark quality standard in premium CBD infused foods, beverages and clinical products.

For more information visit or join our social media network @Phivida.


This corporate update contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, the Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this corporate update. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on This corporate update contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. When used in this corporate update, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should,” and similar expressions, are forward- looking statements. There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this corporate update are made as of the date hereof. Phivida disclaims any intention or obligation to update or revise such information, except as required by applicable law, and Phivida does not assume any liability for disclosure relating to any other company mentioned herein. We seek safe harbour.

Click here to connect with Phivida Holdings Inc (CSE:VIDA) for an Investor Presentation. 


 Aion Therapeutic Inc. (CSE: AION) (” Aion Therapeutic ” or the ” Company “) announced today that its proprietary and patented combinatorial mushroom preparations AION F7 and AION F8 (collectively, the ” Aion Mushroom Preparations ” or ” Preparations “) showed high efficacy in killing HER2+ breast cancer cells, ER+PR+ breast cancer cells, and triple-negative breast cancer cells by direct cytotoxicity.

Keep reading... Show less

The Company Will Tap into Southern Glazer’s Established Distribution Network to Bring Quatreau, its CBD-Infused Sparkling Water, to U.S. Retailers

 Canopy Growth Corporation (“Canopy Growth”) (TSX: WEED) (NASDAQ: CGC), a world-leading diversified cannabis, CBD and vaporization device company, today announced Southern Glazer’s Wine & Spirits (“Southern Glazer’s”), the world’s pre-eminent distributor of beverage alcohol, as the distribution partner for its U.S. portfolio of CBD-infused beverages. This partnership announcement follows the recent launch of Quatreau Canopy’s first line of CBD-infused beverages sold in the U.S market.

Keep reading... Show less

 Canbud Distribution Corporation (CSE: CBDX) (FSE: CD0) (“Canbud” or the “Corporation”) announces its subsidiary Empathy Plant Co. has completed the full development of its vegan multivitamin formula exclusively for women.

Cannot view this image? Visit:
Unique Vegan Women’s Multi-Vitamin with 100% Compostable Packaging

Keep reading... Show less
Cannabis Market Update: Q3 2020 in Review

Click here to read the previous cannabis market update.

During the first few months of investment time in 2021, cannabis faced some volatility alongside optimism about federal changes in the most important market for the drug.

The cannabis business found its stride during Q1 thanks to policy change signals and consolidation.

To find out more, the Investing News Network (INN) asked experts about progress in the market during the first major period of the new year, and which developments investors should watch out for.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

Cannabis market update: New York and US potential boost operations

New York state’s legalization of recreational cannabis was a huge Q1 announcement that added pressure to the US federal government when it comes to cannabis policy, said George Mancheril, co-founder and CEO of Bespoke Financial, a debt financing business with a particular focus on servicing cannabis businesses.

“It’s going to add to the chorus of voices in the federal scene to basically move sooner rather than later,” he explained to INN.

Following the US election in 2020, the momentum for cannabis businesses went on the upswing, as did company valuations, with the idea of expansion at the heart of it all, according to Mancheril.

Before starting Bespoke Financial, Mancheril learned from traditional investment banks, working in the lending, fixed income and debt markets with Goldman Sachs (NYSE:GS) and Guggenheim Partners.

Nawan Butt, portfolio manager with Purpose Investments, agrees with Mancheril. The financial expert told INN the ongoing legalization process seen in the US market is leading to expansion.

“It’s becoming more of a national move, then small pockets of proliferation. That’s very exciting about cannabis right now,” said Butt, who co-manages the Purpose Marijuana Opportunities Fund (NEO:MJJ).

This proliferation effect is causing a change in valuations and enthusiasm for US-based operations. Mancheril told INN that by the end of Q1, multi-state operators (MSOs) had raised approximately US$3.3 billion.

The cannabis lender said he sees the industry as having grown from the woes of 2019; it is now undergoing a return to form as excitement about the US opening up increases.

The expert explained that there is likely to be a windfall of capital in the wake of major federal changes in US cannabis policy, although the timeline for these changes is becoming increasingly hard to predict.

Leading up to that capital influx, Mancheril said he wants to see operators really drill down on the value of desired assets and whether they make sense.

“What I’d hope is that we continue to see bullish sentiment, but with some measure of responsibility, and let’s not just get over ahead of ourselves,” Mancheril told INN. “The idea is let’s minimize the volatility and continue growing responsibly.”


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

As far as struggles go, Butt explained that the cannabis industry has cemented itself as a growth-type sector, and as such there are macro pressures affecting the way these assets operate.

“We’ve seen this preference for cash flows at growth in the current or in the near future, rather than in the far future, and that’s what we’re seeing as far as valuations go in the broad market,” Butt said.

Cannabis market update: Volatility continues to rule as industry foundations build

Despite the industry’s potential and the growing pains it has gone through as a whole in both the US and Canada, volatility remains a key factor in the cannabis investment scene.

Butt explained that the current shareholder base, which is dominated by hedge funds and retail investors, still lacks enough institutional support to avoid the day-to-day volatility cannabis has come to be known for.

These two investor groups, Butt said, can be easily spooked and excited by the news of the day when it comes to their investments.

“A lot of these institutions’ strategies are not about short-term profits, but they’re about long-term sustainability of the businesses themselves,” Butt said.

“That’s why you see a lot of volatility in the space, and that’s essentially what we’ve seen over the past, I’d say, three to two months as well,” he added.

That means investors shouldn’t expect an end to volatility anytime soon.

“It’s not about whether we continue to expect volatility, because we do,” Butt said. “We really think that the volatility will be taken out when the shareholder base becomes more institutional, but it’s really about understanding why there is volatility in the first place.”

Cannabis market update: Canadians talk up US business, but questions remain

A surge of mergers and acquisitions has taken over the Canadian cannabis sector recently as more producers see potential in America.

One of the biggest announcements in this regard came when Organigram Holdings (NASDAQ:OGI,TSX:OGI) secured a C$221 million investment deal from British American Tobacco (NYSE:BTI,LSE:BATS).

Using the funds, the two will work in tandem to develop new branded products designed for the international stage, including in the US. Organigram CEO Greg Engel previously told INN that the US represents a critical opportunity for Canadian companies, but the entry point isn’t as clean as it could be.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

While the long-term potential may be exciting for investors, Butt told INN he’s still unsure how the approach will work for Canadian companies.

The Purpose Investments expert said there will be plenty of space for the biggest Canadian names to pursue US market entries, beyond the initial hemp-derived CBD moves some operators have mde, since the US represents the biggest market in the world.

“But there’s just way too many unknowns right now to say exactly what that participation is going to look like, or when that participation will happen,” he said.

“What we do know is that currently the US MSOs are in a wonderful sort of position to expand on their market leadership that they have. And it will be tough for Canadians to come in and compete with them,” Butt said.

Canadian players still retain the upper hand at times in terms of valuation, which is confusing for both Butt and Dan Ahrens, chief operating officer and portfolio manager at AdvisorShares.

“The performance in quarterly earnings of US companies has been rather spectacular. They’ve knocked it out of the park in most instances,” Ahrens told INN.

Butt praised the recent performance reports from MSOs across the board, pointing to year-over-year growth lines and projections for continued positive performance. In his view, share prices still don’t reflect company value. “Those are really being discounted at this point,” Butt told INN.

“We’ve seen the Canadian licensed producers be really hot stock performance-wise, outpacing the US (MSOs), and I’ll say it’s rather nonsensical to me,” said Ahrens, who oversees the AdvisorShares Pure Cannabis ETF (ARCA:YOLO) and the recently launched AdvisorShares Pure US Cannabis ETF (ARCA:MSOS).

Cannabis market update: Investor takeaway

The cannabis investment proposition finds itself at an interesting moment in time, as the entire sector eagerly awaits confirmation in the US at the federal level.

While for the Canadian companies waiting on the sidelines, this development may feel like a major necessity to address current financial struggles, for US-based operators, the heat around the corner could represent future positivity for already thriving operations.

Keep reading... Show less

 Trulieve Cannabis Corp. (“Trulieve” or the “Company”) (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States will release its first quarter 2021 financial results on Thursday, May 13, 2021 before markets open. Following the earnings release, management will host a conference call at 8:30 AM Eastern Time to review the financial results.

All interested parties can join the conference call by dialing 1-888-231-8191 or 1-647-427-7450, conference ID: 4880609. Please dial in 15 minutes prior to the call to secure a line. The conference call will be archived for replay until May 20, 2021 . To access the archived conference call, please dial 1-855-859-2056 and enter the encore code 4880609.

Keep reading... Show less